ClinicalTrials.gg
TerminatedNCT00845702Updated May 20, 2016Results posted

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

A Phase 3 interventional study of Gadoterate meglumine (Dotarem) and Time of Flight Magnetic Resonance Angiography in Renal Artery Stenosis, sponsored by Guerbet. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Why this study was terminated
lack of recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.

Enrollment
11th of 14
33 · median 64
Started
2009
the only one that year
Phase 3
4 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
1 of 16
Guerbet

Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 3, and was the 9th registered.

Renal Artery Obstruction

59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.

Browse Renal Artery Obstruction studies →

Open to participants now

None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →

Who these studies take

Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Renal Artery Obstruction with a site in United States as a file.
02

Study summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.

Read the detailed description

Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.

03

Conditions studied

  • Renal Artery Stenosis

Keywords

  • Renal artery stenosis
  • Contrast agent
  • MRA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged more than 18 years,
  • Strongly suspected of having renal arterial disease,
  • Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination,

Exclusion criteria

Exclusion Criteria:

  • Known grade IV or V chronic kidney disease (\<30 mL/min/1.73m²),
  • to MRI,
  • Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination,
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Dotarem

    Each subject will receive one injection of Dotarem 0.2 ml/kg.

    Drug: Gadoterate meglumine (Dotarem)

  • Other
    Time Of Flight Magnetic Resonance Angiography

    Each subject undergo a TOF MRA

    Other: Time of Flight Magnetic Resonance Angiography

Interventions

  • Each subject will receive one injection of Dotarem 0.2 ml/kg

  • OtherTime of Flight Magnetic Resonance Angiography

    Each subject will undergo a TOF MRA

06

What researchers measure

Primary outcomes

  1. Percent of Non Assessable Renal Artery Segments

    For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared

    Time frame: 1 to 7 days

07

Results

Posted Sep 19, 2012
Limitations and caveats
The study was not completed due to poor enrollment. The statistical analysis was not performed.

Participant flow

First Patient First Visit: Apr 2009 Last Patient Last Visit: Feb 2010 Location: Radiology centers

TOF MRA
Participant flow — TOF MRA
MilestoneTOF Followed by Dotarem-enhanced MRA
Started33
Completed32
Not completed1
Dotarem MRA
Participant flow — Dotarem MRA
MilestoneTOF Followed by Dotarem-enhanced MRA
Started32
Completed32
Not completed0

Outcome measures

PrimaryPercent of Non Assessable Renal Artery Segments

For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared

Time frame:
1 to 7 days

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem Magnetic Resonance Angiography—1/32 (3.1%)6/32 (18.8%)
Time Of Flight MRA—0/32 (0%)0/32 (0%)
Most frequent serious events
Most frequent serious events
EventDotarem Magnetic Resonance AngiographyTime Of Flight MRA
Mental status changedPsychiatric disorders1/320/32
Most frequent other events
Most frequent other events
EventDotarem Magnetic Resonance AngiographyTime Of Flight MRA
InvestigationInvestigations3/320/32
General disordersGeneral disorders2/320/32
InfectionInfections and infestations1/320/32

Baseline characteristics

Baseline measures were recorded for all 33 patients.

Age, Categorical
Age, Categorical(Participants)TOF and Dotarem Enhanced MRA
<=18 years0
Between 18 and 65 years17
>=65 years16
Age, Continuous
Age, Continuous(years)TOF and Dotarem Enhanced MRA
Mean62 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)TOF and Dotarem Enhanced MRA
Female16
Male17
Region of Enrollment
Region of Enrollment(participants)TOF and Dotarem Enhanced MRA
United States33
08

Study locations

1 site
  • Guerbet LLC
    Bloomington, Indiana 47403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2009
First posted
Feb 18, 2009
Start
Apr 2009
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Sep 19, 2012
Last update
May 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00845702
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Feb 18, 2009
Start date
Apr 2009
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Sep 19, 2012
Last update
May 20, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion